Ozmosi | Emibetuzumab Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

Emibetuzumab

Pronounced as: eh-mee-beh-TOO-zoo-mab

Alternative Names: emibetuzumab, ly2875358
Clinical Status: Active
Latest Update: 2026-01-26
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: c-MET Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Emibetuzumab

Countries in Clinic: Germany, Spain

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2024-514268-18-00

I4C-MC-JTBB

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2024-12-31

12%

2025-05-02

Treatments

Recent News Events

Date

Type

Title